Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug

French drug maker Sanofi said Wednesday that it will acquire Kadmon Pharmaceuticals for $1.9 billion, bolstering its transplant medicines business with a newly approved treatment for graft-versus-host disease.

The all-cash transaction sees Kadmon shares worth $9.50 per share, or a 79% premium to Tuesday’s closing price.

Read the rest…

Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top